Research & Development
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy
20 May 2019 - - The US FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock, US-based Abiomed (NASDAQ: ABMD) said.

This expansion extends the duration of support for each pump from 6 days to 14 days.

The Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilising a patient's hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline.

The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta. Both allow patients to walk around the unit while on support.

Impella heart pumps have FDA PMA approval to treat heart attack patients in cardiogenic shock, and for shock associated with peripartum cardiomyopathy or myocarditis, and have the unique ability to enable the heart to rest and recover, allowing patients to return home with their own heart.

The expanded indication allows for the opportunity to provide longer duration of support for critically ill patients and a longer period of assessment of heart recovery.

One patient who benefited from Impella 5.0 support is Erin Hanussak, then 33 years old, who suffered from myocarditis and went into cardiogenic shock. Her ejection fraction was 15%.

Under the care of Jacob Abraham, MD, a Heart Failure Cardiologist at Providence St. Vincent Medical Center and Medical director of its Center for Advanced Heart Disease, physicians implanted the Impella CP heart pump.

Although Erin's condition improved, the team determined that her heart needed additional support.

Surgeons inserted the Impella 5.0 into her axillary artery, which allowed Erin to begin physical therapy and walk the hospital corridors with hospital staff.

Her kidneys began to improve and after 12 days, the Impella 5.0 was explanted. Erin returned home to her family with her native heart and is back to her busy life as a mom.

The FDA's original PMA approval indicating Impella as safe and effective for the treatment of cardiogenic shock was granted in 2016.

This approval was based on an analysis of 415 patients from the FDA study RECOVER 1 and the US Impella registry, and an Impella literature review of 692 patients in 17 clinical studies.

Additionally, more than 24,000 Impella patients supported by Impella devices were reviewed in a safety analysis.

Based in Danvers, Massachusetts, Abiomed is a provider of medical devices that provide circulatory support.
Login
Username:

Password: